These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35688061)

  • 21. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
    BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
    Denda T; Takashima A; Gamoh M; Iwanaga I; Komatsu Y; Takahashi M; Nakamura M; Ohori H; Sakashita A; Tsuda M; Kobayashi Y; Baba H; Kotake M; Ishioka C; Yamada Y; Sato A; Yuki S; Morita S; Takahashi S; Yamaguchi T; Shimada K
    Eur J Cancer; 2021 Sep; 154():296-306. PubMed ID: 34304054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
    Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
    JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.
    Kadowaki S; Masuishi T; Ura T; Sugiyama K; Mitani S; Narita Y; Taniguchi H; Muro K
    Int J Clin Oncol; 2021 Apr; 26(4):701-707. PubMed ID: 33386556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
    Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
    Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
    Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
    Cremolini C; Marmorino F; Bergamo F; Aprile G; Salvatore L; Masi G; Dell'Aquila E; Antoniotti C; Murgioni S; Allegrini G; Borelli B; Gemma D; Casagrande M; Granetto C; Delfanti S; Di Donato S; Schirripa M; Sensi E; Tonini G; Lonardi S; Fontanini G; Boni L; Falcone A
    Eur J Cancer; 2019 Mar; 109():175-182. PubMed ID: 30735919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
    Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
    Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211
    [No Abstract]   [Full Text] [Related]  

  • 34. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
    Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
    BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
    Kazama K; Shiozawa M; Numata M; Sugano N; Sato S; Uchiyama M; Sato M; Aoyama T; Tamagawa H; Oshima T; Yukawa N; Rino Y
    Int J Colorectal Dis; 2022 Feb; 37(2):337-348. PubMed ID: 34767074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
    Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
    Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
    Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
    Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With
    Rossini D; Antoniotti C; Lonardi S; Pietrantonio F; Moretto R; Antonuzzo L; Boccaccino A; Morano F; Brugia M; Pozzo C; Marmorino F; Bergamo F; Tamburini E; Passardi A; Randon G; Murgioni S; Borelli B; Buonadonna A; Giordano M; Fontanini G; Conca V; Formica V; Aglietta M; Bordonaro R; Aprile G; Masi G; Boni L; Cremolini C
    J Clin Oncol; 2022 Sep; 40(25):2878-2888. PubMed ID: 35666229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.